IRLAB presents at Redeye Neurology Theme Event
Gothenburg, Sweden, October 18, 2024 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that the company will give a presentation at Redeye’s 7th Annual Event on Drug Development in Neurology and Brain Diseases, in Stockholm at 10:05 a.m. on October 23, 2024.
Read More >Watch IRLAB’s
Capital Markets Day 2023!
ISP – The proprietary technology platform
IRLAB’s unique and resource efficient research method, the Integrative Screening Process (ISP), generates the company’s drug pipeline. This proprietary platform is built on a systems pharmacology discovery approach with an extensive, world unique, standardized database on CNS compounds and classes collected over 25 years.
IRLAB’s clinical phase II candidates
Mesdopetam (IRL790)
In development to treat levodopa-induced dyskinesia (LIDs), i.e. involuntary movements occurring upon long-term treatment with levodopa in Parkinson’s disease.
Pirepemat (IRL752)
In development to treat impaired balance (postural dysfunction) leading to falls in Parkinson’s disease.
Q&A with Kristina Torfgård, CEO, at “Investing in Life Science 2024”
Kristina Torfgård, CEO, interviewed at “Investing in Life Science 2024”, an event hosted by BioStock and VatorSecurities, held on September 12, 2024. In Swedish only.
Read More >